Today, fool.com health-care analysts Brenton Flynn and David Williamson look at Pfizer's presentation at the ESMO conference regarding non-small-cell lung cancer. The company's data indicates that its drug provides about double the progression-free survival rate compared with rival products. 

The company's drug is already approved in the U.S., and with a growing number of people getting lung cancer, the drug could be a long-term win for the company.

When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.